Inflammasome‐mediated inflammation and fibrosis: It is more than just the IL‐1β
Muhammad Amir, Mark J. Czaja – 1 September 2017
LiverLearning®: 2017 Webinar: Frailty the “Sixth Vital Sign” in Cirrhosis - How Do We Diagnose It and What Can We Do When We Find It?
Frailty is a critical determinant of outcomes in patients with cirrhosis. In this webinar we will present practical methods to assess and quantify frailty in both the outpatient and inpatient clinical settings. We will also provide recommendations on specific interventions once frailty is identified.Jody Olson (Moderator) Dr.
Significance of definitions of relapse after discontinuation of oral antivirals in HBeAg‐negative chronic hepatitis B
George V. Papatheodoridis, Spilios Manolakopoulos, Tung‐Hung Su, Spyros Siakavellas, Chun‐Jen Liu, Anastasia Kourikou, Hung‐Chih Yang, Jia‐Horng Kao – 31 August 2017 – Relapses are observed in most hepatitis B e antigen (HBeAg)‐negative chronic hepatitis B patients who discontinue treatment with nucleos(t)ide analogues (NAs); however, the rates of relapse vary widely among studies, and whether all patients with relapse need retreatment is unclear.
Continuous renal replacement therapy is associated with reduced serum ammonia levels and mortality in acute liver failure
Filipe S. Cardoso, Michelle Gottfried, Shannan Tujios, Jody C. Olson, Constantine J. Karvellas, For the US Acute Liver Failure Study Group – 31 August 2017 – Hyperammonemia has been associated with intracranial hypertension and mortality in patients with acute liver failure (ALF). We evaluated the effect of renal replacement therapy (RRT) on serum ammonia level and outcomes in ALF. This was a multicenter cohort study of consecutive ALF patients from the United States ALF Study Group registry between January 1998 and December 2016.
Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta‐analysis
Laura Kulik, Julie K. Heimbach, Feras Zaiem, Jehad Almasri, Larry J Prokop, Zhen Wang, M. Hassan Murad, Khaled Mohammed – 31 August 2017 – Patients with hepatocellular carcinoma (HCC) who are listed for liver transplantation (LT) are often treated while on the waiting list with locoregional therapy (LRT), which is aimed at either preventing progression of HCC or reducing the measurable disease burden of HCC in order to receive increased allocation priority. We aimed to synthesize evidence regarding the effectiveness of LRT in the management of patients with HCC who were on the LT waitlist.
Projections of primary liver cancer to 2030 in 30 countries worldwide
Patricia C. Valery, Mathieu Laversanne, Paul J. Clark, Jessica L. Petrick, Katherine A. McGlynn, Freddie Bray – 31 August 2017 – Primary liver cancer (PLC) is the sixth most common cancer worldwide and the second most common cause of cancer death. Future predictions can inform health planners and raise awareness of the need for cancer control action. We predicted the future burden of PLC in 30 countries around 2030. Incident cases of PLC (International Classification of Diseases, Tenth Revision, C22) were obtained from 30 countries for 1993‐2007.
Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta‐analysis
Laura Kulik, Julie K. Heimbach, Feras Zaiem, Jehad Almasri, Larry J Prokop, Zhen Wang, M. Hassan Murad, Khaled Mohammed – 31 August 2017 – Patients with hepatocellular carcinoma (HCC) who are listed for liver transplantation (LT) are often treated while on the waiting list with locoregional therapy (LRT), which is aimed at either preventing progression of HCC or reducing the measurable disease burden of HCC in order to receive increased allocation priority. We aimed to synthesize evidence regarding the effectiveness of LRT in the management of patients with HCC who were on the LT waitlist.
Transmembrane BAX Inhibitor motif‐containing 1, a novel anti‐inflammatory approach for nonalcoholic steatohepatitis treatment
Alexander Wree, Maria Eugenia Inzaugarat, Ariel E. Feldstein – 31 August 2017
Pregnancy in Wilson's disease: Management and outcome
Jan Pfeiffenberger, Sandra Beinhardt, Daniel N. Gotthardt, Nicola Haag, Clarissa Freissmuth, Ulrike Reuner, Annika Gauss, Wolfgang Stremmel, Michael L. Schilsky, Peter Ferenci, Karl Heinz Weiss – 31 August 2017 – Wilson's disease (WD) is a rare inherited disorder of copper metabolism causing toxic hepatic and neural copper accumulation. Clinical symptoms vary widely, from asymptomatic disease to acute liver failure or chronic liver disease with or without neuropsychiatric symptoms.
Performance characteristics of vibration‐controlled transient elastography for evaluation of nonalcoholic fatty liver disease
Raj Vuppalanchi, Mohammad S. Siddiqui, Mark L. Van Natta, Erin Hallinan, Danielle Brandman, Kris Kowdley, Brent A. Neuschwander‐Tetri, Rohit Loomba, Srinivas Dasarathy, Manal Abdelmalek, Edward Doo, James A. Tonascia, David E. Kleiner, Arun J. Sanyal, Naga Chalasani, for the NASH Clinical Research Network – 31 August 2017 – Vibration‐controlled transient elastography estimates liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), which are noninvasive assessments of hepatic fibrosis and steatosis, respectively.